Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 May 9:2019:9781212.
doi: 10.1155/2019/9781212. eCollection 2019.

Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials

Qiu-Ju Lyu  1 , Qiang-Hong Pu  2 , Xian-Fei Zhong  3 , Jin Zhang  1
Affiliations
Free PMC article
Meta-Analysis

Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials

Qiu-Ju Lyu et al. Biomed Res Int. .
Free PMC article

Abstract

Aims: To compare the efficacy and safety of vonoprazan-based versus proton pump inhibitor (PPI)-based triple therapy in the eradication of Helicobacter pylori.

Methods: We performed a systematic search in PubMed, Embase, and the Cochrane Library databases for relevant randomized controlled trials up to March 2019. Studies were included if they compared the efficacy and safety of H. pylori eradication of vonoprazan-based and PPI-based triple therapy.

Results: Three studies with 897 patients were evaluated in this meta-analysis. The H. pylori eradication rate of vonoprazan-based triple therapy was higher than that of PPI-based triple therapy as first-line regimens (intention-to-treat analysis: pooled eradication rates, 91.4% vs 74.8%; odds ratio [OR], 3.68; 95% confidence interval (CI): [1.87-7.26]; P<0.05). The incidence of adverse events in vonoprazan-based triple therapy was lower than that in PPI-based triple therapy (pooled incidence, 32.7% vs 40.5%; OR, 0.71; 95%CI: [0.53-0.95]; P<0.05).

Conclusions: Efficacy of vonoprazan-based triple therapy is superior to that of PPI-based triple therapy for first-line H. pylori eradication. Additionally, vonoprazan-based triple therapy is better tolerated than PPI-based triple therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of study identification, screening, inclusion, and exclusion.
Figure 2
Figure 2
Assessment of bias risk.
Figure 3
Figure 3
Forest plot of vonoprazan versus PPI-based triple therapy for H. pylori eradication in intention-to-treat analysis. CI, confidence interval; PPI, proton pump inhibitor.
Figure 4
Figure 4
Forest plot of vonoprazan versus PPI-based triple therapy for H. pylori eradication in per-protocol analysis. CI, confidence interval; PPI, proton pump inhibitor.
Figure 5
Figure 5
Forest plot of adverse events between vonoprazan versus PPI-based triple therapy. CI, confidence interval; PPI, proton pump inhibitor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hooi J. K. Y., Lai W. Y., Ng W. K., et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–429. doi: 10.1053/j.gastro.2017.04.022. - DOI - PubMed
    1. Hunt R. H., Xiao S. D., Megraud F., et al. Helicobacter pylori in developing countries. World gastroenterology organisation global guideline. Journal of Gastrointestinal and Liver Diseases. 2011;20(3):299–304. - PubMed
    1. Liu W. Z., Xie Y., Lu H., et al. Fifth chinese national consensus report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2) doi: 10.1111/hel.12475.e12475 - DOI - PubMed
    1. Malfertheiner P., Megraud F., O'Morain C. A., et al. Management of Helicobacter pylori infection-the Maastricht V/florence consensus report. Gut. 2017;66(1):6–30. - PubMed
    1. Malfertheiner P., Megraud F., O'Morain C. A., et al. Management of Helicobacter pylori infection—the maastricht IV/ florence consensus report. Gut. 2012;61(5):646–664. doi: 10.1136/gutjnl-2012-302084. - DOI - PubMed

MeSH terms

Substances